Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

Summary

The aim of study is impact of additional treatment with new antidiabetic drugs (semaglutide or empagliflozine) compared to control group in T1DM patients - impact on endothelial function measured by FMD and FPF, arterial stiffness - measured by PWV, inflammatory biomarkers, markers of oxidative stress and endothelial progenitor cells (CD 34+/VDRL2, CD 133+/VDRL2) and correlation with glucovariability or time in range, measured with CGM system.

Timeline

Start

2021-12-15

Primary completion

2022-03-10

Completion

2023-04-20

Drugs

Indications